National Institute on Drug Abuse; Notice of Closed Meetings

---
identifier: "/us/fr/2024-17695"
source: "fr"
legal_status: "authoritative_unofficial"
title: "National Institute on Drug Abuse; Notice of Closed Meetings"
title_number: 0
title_name: "Federal Register"
section_number: "2024-17695"
section_name: "National Institute on Drug Abuse; Notice of Closed Meetings"
positive_law: false
currency: "2024-08-09"
last_updated: "2024-08-09"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2024-17695"
document_type: "notice"
publication_date: "2024-08-09"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "89 FR 65371"
fr_volume: 89
---


#  National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Developing Digital Therapeutics for Substance Use Disorders.

*Date:* September 16, 2024.

*Time:* 1:00 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Shareen Amina Iqbal, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577, *[email protected].*

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools To Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders.

*Date:* September 18, 2024.

*Time:* 12:00 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Shareen Amina Iqbal, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-4577, *[email protected].*

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: August 5, 2024

Lauren A. Fleck,

Program Analyst, Office of Federal Advisory Committee Policy.